Open Access UCL Research: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer https://t.co/wYoBg8gMvB
29a) 👀Check out this @cochranecollab #metaanalysis on the use of #PARPi as #MaintenanceTherapy in recurrent #OvarianCancer (N=1677) 🔗🔓https://t.co/xegR78GaKk PARPi vs placebo 📍PFS: HR 0.34; 95% CI 0.28–0.42 (high‐certainty evidence) 👉No evidence of PD at 1
@drdonsdizon @leitaomd Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library https://t.co/Uxxh9w97Cs
卵巣がん治療におけるポリ(ADPリボース)ポリメラーゼ(PARP)阻害薬 - Tattersall, A - 2022 | Cochrane Library https://t.co/FAcZICg2mO
@leitaomd @IJGConline Awaiting the OS data with interest to add to the review. https://t.co/OjKnaRh9nf
RT @CochraneJapan: PARP阻害薬は卵巣がん患者の生存率を改善するか、またその副作用は何か https://t.co/ytd4HGKmG1
PARP阻害薬は卵巣がん患者の生存率を改善するか、またその副作用は何か https://t.co/ytd4HGKmG1
@DrJoMorrison1 Do PARP inhibitors improve survival in women with ovarian cancer, and what are the side effects? https://t.co/tDaeM25zP3
RT @Cochrane_GNOCG: Just published - Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer @DrJoMorrison1 http…
RT @Cochrane_GNOCG: Just published - Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer @DrJoMorrison1 http…
Just published - Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer @DrJoMorrison1 https://t.co/u9pC1W0DBB
RT @OvcaPapers: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer https://t.co/IeCSQM5HqO
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer https://t.co/IeCSQM5HqO
RT @neilajryan: Very proud to have been part of this Herculean effort led by the awesome @DrJoMorrison1 - PARP improves progression free su…
RT @Cochrane_GNOCG: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Lib…
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library https://t.co/RbMuXX0URy
RT @DrJoMorrison1: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Libr…
Very proud to have been part of this Herculean effort led by the awesome @DrJoMorrison1 - PARP improves progression free survival in ovarian cancer. Jury is out if it increases overall survival but the data is immature.
RT @DrJoMorrison1: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Libr…
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer - Tattersall, A - 2022 | Cochrane Library. Huge effort by Abby, Neil, Alison and Ewelina and a great team to work with. https://t.co/MeMF5bbIIF
#Poly(ADP-ribose) #polymerase (#PARP) #inhibitors for the treatment of #ovarian #cancer (followed by Marc #Lacroix, #Wallonia) https://t.co/Rkx8JyIJa9 #
New article: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer https://t.co/2JqvZppQCG #breastcancer #oncology https://t.co/EvVweOT0Pq